Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 7/20 | 0.52 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | KLK1 | P06870 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20833582 | 0.89 | BTN3A1 (0.43) | BTN3A1ELANEPRTN3RXRARXRB | |
| SCHEMBL22065038 | 0.88 | BTN3A1 (0.48) | BTN3A1ELANEPRTN3KLK1 | |
| SCHEMBL22065040 | 0.88 | BTN3A1 (0.48) | BTN3A1ELANEPRTN3MRGPRX4 | |
| SCHEMBL18973698 | 0.88 | BTN3A1 (0.48) | BTN3A1ELANEPRTN3 | |
| SCHEMBL24505391 | 0.86 | BTN3A1 (0.60) | BTN3A1ELANEPRTN3KLK1 | |
| SCHEMBL18973549 | 0.86 | BTN3A1 (0.60) | BTN3A1ELANEPRTN3KLK1 | |
| SCHEMBL18973571 | 0.86 | BTN3A1 (0.52) | BTN3A1ELANEPRTN3KLK1 | |
| SCHEMBL22065041 | 0.85 | BTN3A1 (0.49) | BTN3A1ELANEPRTN3KLK1 | |
| SCHEMBL22065042 | 0.85 | BTN3A1 (0.49) | BTN3A1ELANEPRTN3KLK1 | |
| SCHEMBL18973567 | 0.84 | BTN3A1 (0.55) | BTN3A1ELANEPRTN3PPARGKLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402962-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2022-12-22 | — | — | US | disclosed |
| US-20210009625-A1 | DIASTEREOSELECTIVE SYNTHESIS OF PHOSPHATE DERIVATIVES | LAURUS LABS PRIVATE LTD (IN) | 2021-01-14 | — | — | US | disclosed |
| US-10774104-B2 | Diastereoselective synthesis of phosphate derivatives | LAURUS LABS PRIVATE LTD (IN) | 2020-09-15 | — | — | US | disclosed |
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2020-06-11 | — | — | US | disclosed |
| US-20200181190-A1 | SYNTHESIS OF 3'-DEOXYADENOSINE-5'-O-[PHENYL(BENZYLOXY-L-ALANINYL)]PHOSPHATE (NUC-7738) | NuCana plc (GB) | 2020-06-11 | — | — | US | disclosed |
| WO-2017098252-A1 | DIASTEREOSELECTIVE SYNTHESIS OF PHOSPHATE DERIVATIVES AND OF THE GEMCITABINE PRODRUG NUC-1031 | NUCANA BIOMED LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774104-B2 | Diastereoselective synthesis of phosphate derivatives | TYMP, PNP, DPYD | BTN3A1 4678/4885ELANE 4526/4885PRTN3 1874/4885 |
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | PPA1, PPIP5K2, TYMP | BTN3A1 4531/4885ELANE 4653/4885PRTN3 1013/4885 |
| US-20220402962-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | PNP, NTPCR, TYMP | BTN3A1 2948/4885ELANE 3870/4885PRTN3 724/4885 |
| US-20210009625-A1 | DIASTEREOSELECTIVE SYNTHESIS OF PHOSPHATE DERIVATIVES | TYMP, PNP, DPYD | BTN3A1 4228/4885ELANE 4731/4885PRTN3 2082/4885 |
| US-20200181190-A1 | SYNTHESIS OF 3'-DEOXYADENOSINE-5'-O-[PHENYL(BENZYLOXY-L-ALANINYL)]PHOSPHATE (NUC-7738) | PNP, NT5C2, DUT | BTN3A1 3995/4885ELANE 3725/4885PRTN3 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.